APRICUS BIOSCIENCES

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros®, for the treatment of ED. Vitaros® is approved in Europe and Canada and will be commercialized by Apricus’ marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), and Bracco SpA. Femprox®, the Company’s product candidate for the treatment of FSAID, has successfully completed a nearly 400-subject proof-of-concept study.